OTLK News and Press, Outlook Therapeutics Inc. From 03/22/24

2024-03-22 08:32:44 ET More on Outlook Therapeutics Outlook Therapeutics falls on 1-for-20 reverse stock split Outlook Therapeutics stock climbs 13% amid Chardan upgrade Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for ...

Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the fir...

2024-03-18 22:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed...

2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-13 09:02:02 ET Otter Lake Resources Inc (OTLK) announced stock split at a ratio of 1-for-20 on 2024-03-14 ... Full story available on KlickAnalytics.com

2024-03-12 15:14:22 ET More on Outlook Therapeutics Outlook Therapeutics stock climbs 13% amid Chardan upgrade Outlook stock rallies on private placement, FDA study agreement Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data...

ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a 1...

2024-02-15 14:52:59 ET More on Outlook Therapeutics Outlook stock rallies on private placement, FDA study agreement Outlook Therapeutics GAAP EPS of -$0.24 Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therap...

2024-02-14 08:12:17 ET More on Outlook Therapeutics Outlook stock rallies on private placement, FDA study agreement Outlook Therapeutics GAAP EPS of -$0.24 Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therap...